Targeting Hypoxia-Inducible Factor-1α (HIF-1α) in Combination With Antiangiogenic Therapy: A Phase I Trial of Bortezomib Plus Bevacizumab

Oncotarget - United States
doi 10.18632/oncotarget.2163
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Tissue Expression of Hypoxia-Inducible Factor 1 Alpha (HIF-1A) in Wilms Tumor

Journal of Dr Behcet Uz Children s Hospital
2019English

Increased Antitumor Activity of Bevacizumab in Combination With Hypoxia Inducible Factor-1 Inhibition

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Hypoxia-Inducible Factor-1α Induces Multidrug Resistance Protein in Colon Cancer

OncoTargets and Therapy
OncologyPharmacology
2015English

A Dynamic Model of the Hypoxia-Inducible Factor 1 (HIF-1 ) Network

Journal of Cell Science
Cell Biology
2013English

Natural Product-Based Inhibitors of Hypoxia-Inducible Factor-1 (HIF-1)

Current Drug Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2006English

Correction: The Role of Hypoxia Inducible Factor-1 Alpha in Bypassing Oncogene-Induced Senescence

PLoS ONE
Multidisciplinary
2014English

Expression Significance and Potential Mechanism of Hypoxia‐inducible Factor 1 Alpha in Patients With Myelodysplastic Syndromes

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Targeting the Hypoxia-Inducible Factor (HIF) Pathway in Cancer

Expert Reviews in Molecular Medicine
Molecular MedicineMolecular Biology
2009English

P300 Relieves P53-Evoked Transcriptional Repression of Hypoxia-Inducible Factor-1 (HIF-1)

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy